TITLE

FDA Gout Route Unimpeded, but Will Docs Jump Aboard?

AUTHOR(S)
Osborne, Randy
PUB. DATE
March 2010
SOURCE
BioWorld Insight;3/29/2010, Vol. 18 Issue 13, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers updates on various pharmaceutical companies including Savient Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and BioCryst Pharmaceuticals Inc. New Jersey-based Savient resubmits its biologics license application for Krystexxa in refractory patients. Takeda in Japan encourages rheumatologists and primary-care physicians to accept a new drug in replace of allopurinol. Meanwhile, BioCryst waits the result of the Phase II trials of its nucleoside phosphorylase inhibitor.
ACCESSION #
48966479

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics